Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 1/20 | 0.50 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | CHRNA1 | P02708 | 1/20 | 0.31 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.31 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Imidaclothiz SCHEMBL238122 | 0.88 | CHRNB2 (0.55) | CHRNB2CHRNA4SMN1; SMN2CYP1A2CYP3A4 | |
| Imidaclothiz SCHEMBL676082 | 0.88 | CHRNB2 (0.55) | CHRNB2CHRNA4SMN1; SMN2CYP1A2CYP3A4 | |
| SCHEMBL237765 | 0.87 | CHRNB2 (0.49) | CHRNB2CHRNA4SMN1; SMN2CYP1A2CYP3A4 | |
| SCHEMBL237015 | 0.87 | CHRNB2 (0.49) | CHRNB2CHRNA4SMN1; SMN2CYP1A2CYP3A4 | |
| SCHEMBL9069331 | 0.87 | CHRNB2 (0.49) | CHRNB2CHRNA4SMN1; SMN2CYP1A2CYP3A4 | |
| SCHEMBL9069332 | 0.87 | CHRNB2 (0.49) | CHRNB2CHRNA4SMN1; SMN2CYP1A2CYP3A4 | |
| SCHEMBL9069000 | 0.87 | CHRNB2 (0.49) | CHRNB2CHRNA4SMN1; SMN2CYP1A2CYP3A4 | |
| SCHEMBL7982213 | 0.81 | CHRNB2 (0.48) | CHRNB2CHRNA4SMN1; SMN2CYP1A2CYP3A4 | |
| SCHEMBL9068969 | 0.80 | CHRNB2 (0.43) | CHRNB2CHRNA4SMN1; SMN2CYP1A2CYP3A4 | |
| SCHEMBL7981821 | 0.78 | CHRNB2 (0.55) | CHRNB2CHRNA4SMN1; SMN2CYP3A4ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2225940-B1 | Oil dispersions of nAChR binding neonicotinoids | GAT MICROENCAPSULATION GMBH (AT) | 2014-03-12 | — | — | EP | disclosed |
| US-8293733-B2 | Oil dispersions of nAChR binding neonicotinoids | GAT MICROENCAPSULATION AG (AT) | 2012-10-23 | — | — | US | disclosed |
| US-20120004104-A1 | OIL DISPERSIONS OF nAChR BINDING NEONICOTINOIDS | GAT MICROENCAPSULATION AG (AT) | 2012-01-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120004104-A1 | OIL DISPERSIONS OF nAChR BINDING NEONICOTINOIDS | CHRND, ITGAM, CHRM2 | CHRNB2 21/4885CHRNA4 10/4885SMN1; SMN2 626/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.